These CAR-T cells, in a dose equivalent to 108 CAR CD8 T cells/kg, were able to reverse T cell exhaustion, decreasing 30–70% expression of exhaustion markers in tumor-infiltrating lymphocytes (TILs). The gene discussed is CD8A; the disease is neoplasm.